Sukh Dev Singh Khalsa
Psychiatric/Mental Health · Riverside, CANPI 1881978682
Payments from drug & device makers
Across 201 payments — averaging $17.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$683
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$395
- Alkermes, Inc.$311
- Supernus Pharmaceuticals, Inc.$294
- Takeda Pharmaceuticals U.S.A., Inc.$282
- Otsuka America Pharmaceutical, Inc.$261
- plus $1K from 17 others
What the payments were for
- Food & beverage$3,51399%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 33 | $683 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $395 |
| Alkermes, Inc. | 20 | $311 |
| Supernus Pharmaceuticals, Inc. | 34 | $294 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $282 |
| Otsuka America Pharmaceutical, Inc. | 15 | $261 |
| AbbVie | 13 | $260 |
| Bausch Health US, LLC | 11 | $229 |
| Johnson & Johnson | 8 | $159 |
| Vanda Pharmaceuticals Inc. | 7 | $138 |
| Teva Pharmaceuticals USA, Inc. | 6 | $127 |
| Ironshore Pharmaceuticals Inc. | 3 | $74 |
| Noven Therapeutics, LLC | 4 | $69 |
| Almatica Pharma LLC | 3 | $57 |
| Eisai Inc. | 3 | $55 |
| Neurocrine Biosciences, Inc. | 2 | $41 |
| Corium, LLC | 1 | $23 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Alfasigma USA, Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Adlon Therapeutics L.p. | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$121
How this compares
$3,560 in reported general payments places this provider in the 85th percentile of 2,433 psychiatric/mental health providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 13 | $110,771 |
| AplenzinBupropion Hbr | 23 | $89,415 |
| LybalviOlanzapine/Samidorphan Malate | 32 | $48,668 |
| TrintellixVortioxetine Hydrobromide | 52 | $28,249 |
| RexultiBrexpiprazole | 11 | $15,925 |
| VyvanseLisdexamfetamine Dimesylate | 31 | $11,724 |
| Lurasidone Hcl | 61 | $9,781 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 38 | $9,726 |
| Aripiprazole | 113 | $6,281 |
| BelsomraSuvorexant | 14 | $6,274 |
| LinzessLinaclotide | 11 | $5,792 |
| Dyanavel XrAmphetamine | 12 | $5,166 |
| Doxepin Hcl | 104 | $4,368 |
| Duloxetine Hcl | 196 | $4,192 |
| Trazodone Hcl | 174 | $3,987 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $41 | $110,77113 claims |
| Bausch Health US, LLCAplenzin | $229 | $89,41523 claims |
| Alkermes, Inc.Lybalvi | $311 | $48,66832 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $282 | $39,97383 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $261 | $15,92511 claims |
| AbbVieLinzess | $260 | $5,79211 claims |
| Almatica Pharma LLCSertraline Hcl | $57 | $1,456142 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,433 psychiatric/mental health providers in California.
Other psychiatric/mental health in Riverside
- Carey MartinMillbrae$745K
- Liberty MaciasRedlands$288K
- Joshua BurgettSacramento$239K
- Jovita Ezirim-SalamialofojeLos Angeles$162K
- Angie-Kolleen TanThousand Oaks$159K
- Thy LamVista$121K
- David OhIrvine$72K
- Samantha PerkinsAnaheim$49K
- Yvette ElpidioOrange$43K
- Sarah KoLos Angeles$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.